About Cochlear (ASX: COH)
Cochlear Limited develops and sells implantable hearing solutions for children and adults across markets worldwide. The company's core business spans cochlear implant systems, sound processor upgrades, bone conduction systems, and related accessories, serving patients through a broad portfolio of hardware and software hearing technologies.
Its product range includes the Nucleus family of offerings, covering Nucleus sound processors, Nucleus implants, and a smart bimodal hearing solution, alongside the Baha range of bone conduction products, which encompasses the Baha 6 Max sound processor and the Baha implant. Complementary accessories such as wireless devices and Nucleus water-safe accessories round out the portfolio. Founded in 1981, Cochlear is headquartered in Sydney, Australia.
MFAM Research
- [BUY] Cochlear (ASX: COH) – Oversold In TurmoilMay 7, 2025Cochlear (ASX: COH) is one of the world’s leading health technology firms with global dominance in the internal and external hearing aid space. The stock has reacted sharply to tariff concerns and its impact on the company along with cost overruns and disappointing growth in some operating segments. However, we believe the company presents excellent […]
Latest Announcements
- Cochlear (ASX: COH) – FY26 Earnings Guidance Reduced Amid Trading ChallengesApril 22, 2026Cochlear Limited has reduced its FY26 underlying net profit guidance to $290-330 million, down from previous expectations, citing softer-than-expected trading conditions in developed markets and heightened uncertainty from Middle Eastern conflicts. The announcement, made on 22 April 2026, represents a material reassessment of the company’s earnings trajectory and reflects a confluence of operational and macroeconomic […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Medical Devices |
|---|---|
No other covered stocks. |